–
Статьи в журналах
-
- 2023 Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
- Ascierto PA, Stroyakovskiy D., Gogas H., Robert C., Lewis K., Protsenko S., Pereira RP, Eigentler T., Rutkowski P., Demidov L., Zhukova N., Schachter J., Yan Y., Caro I., Hertig C., Xue C., Kusters L., McArthur GA, Gutzmer R.
- в журнале Lancet Oncology, издательство The Lancet Publishing Group (United Kingdom), том 2, № 1, с. 33-44 DOI